Novavax Statistics
Total Valuation
Novavax has a market cap or net worth of $1.82 billion. The enterprise value is $1.56 billion.
Market Cap | 1.82B |
Enterprise Value | 1.56B |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, before market open.
Earnings Date | Aug 6, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Novavax has 140.40 million shares outstanding. The number of shares has increased by 62.39% in one year.
Shares Outstanding | 140.40M |
Shares Change (YoY) | +62.39% |
Shares Change (QoQ) | +38.85% |
Owned by Insiders (%) | 4.99% |
Owned by Institutions (%) | 58.28% |
Float | 122.46M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 10.84 |
PS Ratio | 1.83 |
Forward PS | 1.98 |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 1.56 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.90
Current Ratio | 0.90 |
Quick Ratio | 0.64 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -26.84 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -24.60% |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | $645,890 |
Profits Per Employee | -$258,397 |
Employee Count | 1,543 |
Asset Turnover | 0.61 |
Inventory Turnover | 14.77 |
Taxes
In the past 12 months, Novavax has paid $3.11 million in taxes.
Income Tax | 3.11M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +75.75% in the last 52 weeks. The beta is 1.95, so Novavax's price volatility has been higher than the market average.
Beta (5Y) | 1.95 |
52-Week Price Change | +75.75% |
50-Day Moving Average | 11.91 |
200-Day Moving Average | 7.04 |
Relative Strength Index (RSI) | 44.89 |
Average Volume (20 Days) | 15,057,284 |
Short Selling Information
The latest short interest is 39.71 million, so 28.28% of the outstanding shares have been sold short.
Short Interest | 39.71M |
Short Previous Month | 38.21M |
Short % of Shares Out | 28.28% |
Short % of Float | 32.42% |
Short Ratio (days to cover) | 1.87 |
Income Statement
In the last 12 months, Novavax had revenue of $996.61 million and -$398.71 million in losses. Loss per share was -$3.13.
Revenue | 996.61M |
Gross Profit | 627.72M |
Operating Income | -398.57M |
Pretax Income | -395.60M |
Net Income | -398.71M |
EBITDA | -337.06M |
EBIT | -381.39M |
Loss Per Share | -$3.13 |
Balance Sheet
The company has $491.04 million in cash and $229.33 million in debt, giving a net cash position of $261.71 million or $1.86 per share.
Cash & Cash Equivalents | 491.04M |
Total Debt | 229.33M |
Net Cash | 261.71M |
Net Cash Per Share | $1.86 |
Equity (Book Value) | -867.08M |
Book Value Per Share | -6.18 |
Working Capital | -77.26M |
Cash Flow
In the last 12 months, operating cash flow was -$471.93 million and capital expenditures -$42.50 million, giving a free cash flow of -$514.43 million.
Operating Cash Flow | -471.93M |
Capital Expenditures | -42.50M |
Free Cash Flow | -514.43M |
FCF Per Share | -$3.68 |
Margins
Gross margin is 62.99%, with operating and profit margins of -39.99% and -40.01%.
Gross Margin | 62.99% |
Operating Margin | -39.99% |
Pretax Margin | -39.69% |
Profit Margin | -40.01% |
EBITDA Margin | -33.82% |
EBIT Margin | -38.27% |
FCF Margin | -51.62% |
Dividends & Yields
Novavax does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -62.39% |
Shareholder Yield | -62.39% |
Earnings Yield | -21.89% |
FCF Yield | -28.25% |
Analyst Forecast
The average price target for Novavax is $19.00, which is 46.49% higher than the current price. The consensus rating is "Buy".
Price Target | $19.00 |
Price Target Difference | 46.49% |
Analyst Consensus | Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | -2.34% |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 10, 2019. It was a reverse split with a ratio of 1:20.
Last Split Date | May 10, 2019 |
Split Type | Reverse |
Split Ratio | 1:20 |
Scores
Novavax has an Altman Z-Score of -4.91 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -4.91 |
Piotroski F-Score | 2 |